Print Page   |   Contact Us   |   Sign In   |   Join iBIO
Industry News


TOP industry news from Business Wire

Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer CenterOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson

 

Cellectis annonce la première administration de UCART123 chez un patient atteint de leucémie à cellules dendritiques plasmacytoïdes dans le cadre de son étude clinique de Phase I menée au MD Anderson Cancer CenterOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext : ALCLS - Nasdaq : CLLS), société biopharmaceutique de stade clinique, spécialisée dans le développement d'immunothérapies fondées sur des cellules CAR-T ingénierées (UCART), annonce que le produit candidat UCART123 contrôlé par Cellectis et ingénieré grâce à la technologie d’édition du génome TALEN® a été administré à un premier patient atteint de leucémie à cellules dendritiques plasmacytoïdes (LpDC)

 

LYNPARZA® (olaparib) Receives Additional FDA Approval in the US for Ovarian CancerOpen in a New Window

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the U.S. and Canada) today announced that the US Food and Drug Administration (FDA) has granted approval for the PARP inhibitor, LYNPARZA® (olaparib), as follows: New use of LYNPARZA tablets as a maintenance treatment of adult patients with recurrent, epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, regard

 

LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian CancerOpen in a New Window

KENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer

 

Global Collagen Biomaterial Market - Opportunities and Forecast (2017-2022) - Chiefly Driven By Rising Incidences of Orthopaedic Disorders - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Global Collagen Biomaterial Market: Analysis By Source, By Application, By Region, By Country: Opportunities and Forecast (2017-2022)" report has been added to Research and Markets' offering. The global collagen biomaterial market is projected to display a robust growth represented by a CAGR of 9.15% during 2017-2022, chiefly driven by aging population and rising incidences of orthopaedic disorders. Over the recent years, the global Collagen Biomaterial industry ha

 

Samenvatting: PsiOxus Therapeutics kondigt nieuwe benoemingen binnen directie aan: versterkt aanwezigheid in VSOpen in a New Window

OXFORD, Engeland & PHILADELPHIA--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus) heeft vandaag aangekondigd dat Charles Rowland en Duncan Higgons zijn toegetreden tot de raad van bestuur. Deze benoeming maakt deel uit van de doorlopende inspanningen van het bedrijf voor uitbreiding in de Verenigde Staten. Charles Rowland was hiervoor president en CEO van Aurinia Pharmaceuticals, een farmaceutisch bedrijf in klinisch-wetenschappelijk onderzoek naar lupus nefritis. Voorafgaand aan deze func

 

QPharma Expands Footprint with Somerset-area OfficeOpen in a New Window

MORRISTOWN, N.J.--(BUSINESS WIRE)--#pharma--QPharma, a commercial and compliance leader, is expanding its footprint with the opening of a new office in the Somerset area of New Jersey.

 

Global Molecular Spectroscopy Market - Trends and Forecast to 2024 - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Global Molecular Spectroscopy Market - Trends and Forecast to 2024" report has been added to Research and Markets' offering. Synopsis: Global Molecular Spectroscopy Market is expected to reach USD 6.712 billion by 2024, at a CAGR of 5.0% during the forecast period of 2017 to 2024. The report contains 321 pages of exclusive premium insights with 300 tables and 29 figures. The Global Molecular Spectroscopy Market has been segmented On the basis of technology the mark

 

Exalenz Bioscience Launches Automated BreathID® Hp Lab Urea Breath Testing System For Helicobacter pylori DetectionOpen in a New Window

MANASQUAN, N.J.--(BUSINESS WIRE)--Exalenz Bioscience Launches Automated BreathID® Hp Lab Urea Breath Testing System For Helicobacter pylori Detection

 

Fresenius Kabi and AABB Unveil New Website for Annual Blood Collectors WeekOpen in a New Window

LAKE ZURICH, Ill. & BETHESDA, Md.--(BUSINESS WIRE)--#BloodCollectorsWeek--Fresenius Kabi and AABB, today announced the introduction of a new and improved Blood Collectors Week website - www.bloodcollectors.org - in advance of the 12th annual Blood Collectors Week. This year the celebratory week is September 3 – 9. Blood Collectors Week was co-created by Fresenius Kabi and AABB to recognize and honor blood collectors, the vital link between donors and patients in need of blood. This year’s celebration will feature mo

 

New Terahertz Imaging Approach Could Speed Up Skin Cancer DetectionOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--#CancerDetection--Researchers show that subwavelength terahertz imaging works with methods that accelerate imaging speed, which can enhance skin cancer detection.

 

Covalon To Feature IV Clear at APHON Pediatric ConferenceOpen in a New Window

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be featuring IV Clear while exhibiting for the first time at the 41st Association of Pediatric Hematology/Oncology Nurses annual conference and exhibit at the Palm Springs Convention Center, from August 17-19, 2017. Along with IV Clear, Covalon will feature its proprietary line of infection management dressings for both

 

Resumen: Scientist.com se coloca en el puesto 155 en la Lista de 2017 de la revista Inc de las 5.000 empresas con mayor crecimientoOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Scientist.com, el mercado líder de servicios científicos externalizados, ha anunciado que ha sido clasificado en el puesto 155 en la Lista de 2017 de la revista Inc. de las 5.000 empresas de capital privado con más rápido crecimiento de América en la categoría de Salud. La empresa con sede en San Diego crea mercados privados que conectan a muchas de las mayores organizaciones de investigación de ciencias de la vida privadas del mundo con una red mundial de miles de p

 

Protalex Awarded Grant from FDA Office of Orphan Products Development to Foster Clinical Development of PRTX-100 for the Treatment of Immune ThrombocytopeniaOpen in a New Window

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded the Company a $403,000 grant to support future clinical development activity of PRTX-100 as a treatment for Immune Thrombocytopenia (ITP). The goal of FDA's OOPD Orphan Products Clinical Trials Grants Program is to encourage the clinical development of new drugs for

 

Alzeca Biosciences Closes $11 Million Series A FinancingOpen in a New Window

HOUSTON--(BUSINESS WIRE)--#AlzheimersDisease--Alzeca Biosciences Closes $11 million Series A Financing Supporting Development of MRI Imaging Agent for Early Alzheimer's Disease Detection.

 

Kite Highlights Publication from the National Cancer Institute Demonstrating Responses in Patients with Metastatic Solid Tumors Treated with T Cell Receptor (TCR) Therapy Targeting MAGE A3Open in a New Window

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today highlighted the publication of results in the Journal of Clinical Oncology from a National Cancer Institute (NCI) study evaluating the safety and efficacy of a MAGE A3 T cell receptor (TCR) engineered T-cell therapy. The cancer testis antigen MAGE A3 is frequently found in many cancers including bladder, esophageal, cervical, head and neck, lung, and ovarian cancers, among others. The r

 

Resumen: PsiOxus Therapeutics anuncia dos nuevas incorporaciones al Consejo que refuerzan la presencia de la empresa en EE. UU.Open in a New Window

OXFORD, Inglaterra & FILADELFIA--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus) ha anunciado el nombramiento de Charles Rowland y Duncan Higgons al Consejo de Administración como parte del actual impulso para la expansión en Estados Unidos. Charles Rowland ha sido más recientemente presidente y CEO de Aurinia Pharmaceuticals, una empresa farmacéutica de estado clínico centrada en el mercado mundial de la nefritis lúpica. Duncan Higgons ha formado parte del Consejo de Administración de Jo

 

PsiOxus Therapeutics annonce deux nouvelles nominations au sein de sa direction : les nouveaux membres du conseil renforcent la présence de la société aux Etats-UnisOpen in a New Window

OXFORD, Royaume-Uni & PHILADELPHIE--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus) a annoncé aujourd'hui la nomination de Charles Rowland et Duncan Higgons au Comité de direction dans le cadre de sa démarche continue d'expansion aux Etats-Unis. Charles Rowland était récemment le Président et Chief Executive Officer (CEO) de Aurinia Pharmaceuticals, une société pharmaceutique spécialisée dans la recherche clinique sur le marché mondial du lupus néphrétique. Il fut auparavant Vice Presiden

 

Endologix Announces Positive Clinical Results from the LEOPARD Clinical StudyOpen in a New Window

IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced positive interim results from the LEOPARD (Looking at Evar Outcomes by Primary Analysis of Randomized Data) clinical study. LEOPARD is the first and only head-to-head, prospective, multi-center, randomized clinical study comparing currently available endovascular abdominal aortic stent grafts. LEOPARD directly compares the Endologix AFX® and AFX

 

Atreca Completes Oversubscribed $35 Million Series B Financing to Advance Novel Cancer ImmunotherapiesOpen in a New Window

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today the completion of its Series B round of financing with a total investment of $35 million. The financing was co-led by new investor Wellington Management Company LLP and by a large US-based, healthcare-focused fund, participating as an existing Atreca investor. Additional participation included new invest

 

Helix Teams Up with Illumina Accelerator to Drive Innovation and DNA-Powered Products for ConsumersOpen in a New Window

SAN CARLOS, Calif.--(BUSINESS WIRE)--#DNA--Calling innovative startups building consumer applications to deliver DNA insights powered by Helix’s Exome+ and next generation sequencing

 

Spectrum Pharmaceuticals to Present Corporate Update at the 2017 Southern California Investor Conference in Newport Beach on Thursday, August 24thOpen in a New Window

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals to Present Corporate Update at the 2017 Southern California Investor Conference in Newport Beach on Thursday, August 24th

 

AgeX Therapeutics Closes $10 Million Capital RaiseOpen in a New Window

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), announced today that it has closed its round of equity financing, raising net proceeds of $10 million, valuing AgeX at approximately $68 million post-money. Post-closing, BioTime owns approximately 85% of the outstanding shares of AgeX. The financing, first announced on August 2, 2017, is expected to fund AgeX’s general operations and product development well into 2019, while sa

 

Kiadis Pharma obtains up to €15 million debt financing from Kreos CapitalOpen in a New Window

AMSTERDAM-DUIVENDRECHT, The Netherlands--(BUSINESS WIRE)--Regulatory News: Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces that it has obtained a debt facility of up to €15 million from Kreos Capital. The loan consists of two tr

 

Context Therapeutics Initiates Collaborations with Three Leading Research Partners on the Biology of Sigma1Open in a New Window

PHILADELPHIA--(BUSINESS WIRE)--#cancer--Context Therapeutics Initiates Collaborations with Three Leading Research Partners on the Biology of Sigma1

 

PsiOxus Therapeutics gibt zwei neue Bestellungen in das Board bekannt: Neue Board-Ernennungen stärken die Präsenz des Unternehmens in den USAOpen in a New Window

OXFORD, England und PHILADELPHIA--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus) meldete heute die Bestellung von Charles Rowland und Duncan Higgons in das Board of Directors im Rahmen der laufenden Anstrengungen zur Expansion in den USA. Charles Rowland war zuletzt President und Chief Executive Officer (CEO) von Aurinia Pharmaceuticals, ein Pharmaunternehmen mit klinischen Entwicklungsprodukten, das sich auf den weltweiten Lupusnephritis-Markt konzentriert. Zuvor war er als Vice Preside

 

$2.69 Billion Biobanking Market 2017 by Product and Service, Sample Type, Applications - Global Forecast to 2022 - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Biobanking Market by Product and Service(Equipment, Consumable, Services, Software), Sample Type (Blood Products, Human Tissues, Cell Lines, Nucleic Acid), Application(Regenerative Medicine, Life Science, Clinical Research) - Global Forecast to 2022" report has been added to Research and Markets' offering. The biobanking market is expected to reach USD 2.69 billion by 2022 from USD 1.85 billion in 2017, at a CAGR of 7.8%. Factors driving the growth of this market i

 

Riassunto: PsiOxus Therapeutics annuncia due nuove nomine al CdA e rafforza la presenza negli Stati UnitiOpen in a New Window

OXFORD, Inghilterra, e FILADELFIA--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus) ha oggi annunciato la nomina di Charles Rowland e Duncan Higgons nel Consiglio di amministrazione, nell'ambito dell'attuale strategia di espansione negli Stati Uniti. Di recente Charles Rowland ha ricoperto la carica di presidente e amministratore delegato di Aurinia Pharmaceuticals, una casa farmaceutica di ricerca clinica specializzata nel settore globale della nefrite lupica. In precedenza è stato vicepr

 

PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US PresenceOpen in a New Window

OXFORD, England & PHILADELPHIA--(BUSINESS WIRE)--PsiOxus Press Release - New Board Appointments

 

New Data Shows Previously Allergic Children Still Able to Tolerate Peanut Four Years after Treatment with a Novel Immunotherapy Licensed by Prota TherapeuticsOpen in a New Window

MELBOURNE, Australia--(BUSINESS WIRE)--New data shows previously allergic children still able to tolerate peanut four years after treatment with a novel immunotherapy licensed by Prota.

 

Medpace Holdings, Inc. Announces Stock Repurchase Agreement with CinvenOpen in a New Window

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced it has entered into a stock repurchase agreement (the “Stock Repurchase Agreement”) with investment funds affiliated with Cinven Capital Management (V) General Partner Limited (“Cinven”). Under the terms of the Stock Repurchase Agreement with Cinven, Medpace has agreed to repurchase 2,000,000 shares of Medpace’s common stock, at a purchase price of $30.27 per share, representing aggregate consideratio
Association Management Software Powered by YourMembership  ::  Legal